NB-002: Long-Acting Amylin Analog

A best-in-class long-acting amylin analog targeting the $15B metabolic disease market, specifically obesity and type 2 diabetes mellitus (T2DM). This injectable hormone therapy acts as an amylin/calcitonin receptor agonist with weekly dosing convenience.

NB-002: Best-in-Class Long-Acting Amylin Analog

Addressing the Obesity Epidemic

NB-002 is a best-in-class long-acting amylin analog targeting the **$15B metabolic disease market**, specifically obesity and type 2 diabetes mellitus (T2DM). This injectable hormone therapy acts as an amylin/calcitonin receptor agonist with weekly dosing convenience.

The program is currently in IND-enabling studies with **strong global patent protection**. NB-002's innovative formulation platform enables both monotherapy and combination approaches with GLP-1 receptor agonists, offering unprecedented flexibility in treating metabolic disorders.

Weekly Injectable

Convenient once-weekly administration improves patient compliance and treatment adherence

Dual Stability Platform

Unique formulations stable across broad pH ranges enable flexible combination strategies

Combination Ready

Designed for synergistic combinations with GLP-1RAs like semaglutide and tirzepatide

NB-002: Superior Weight Loss and Extended Half-Life

Innovative Formulation Platform

NB-002's diverse combination platform covers a broad pH range with two distinct formulation strategies: **acid-stable analogs (pH 3.0-5.0)** and **neutral-stable analogs (pH 6.0-7.5)**. This versatility enables optimal formulation with various combination partners, including market-leading GLP-1 receptor agonists.



Monotherapy Weight Loss

At 30 nmol/kg in DIO rats, exceeding Cagrilintide's 15.86% performance



Extended Half-Life

Longer duration observed versus Cagrilintide in cynomolgus monkey studies

Best-in-Class Combination Potential

NB-002 demonstrates **superior potential in weight management** both as monotherapy and in combination with GLP-1RAs such as semaglutide or tirzepatide. Preclinical studies show advantages over competing amylin analogs combined with identical GLP-1 partners, suggesting enhanced mechanistic synergy.

Comprehensive off-target toxicity and dose-ranging studies confirm an **excellent safety profile**, supporting confident dose escalation in clinical development and enabling exploration of higher, more efficacious doses that may be prohibited for competing molecules.

Accelerating Innovation to Improve Patients' Lives

Navika Bio connects groundbreaking biotech innovation with global pharmaceutical partners to deliver transformative therapies to patients worldwide.

NAVIKA BIO

Let's Connect

For more information about partnership opportunities and to join us on this exciting journey of bringing transformative therapies to patients worldwide, please reach out to:

Lawrence Hu, PhD

Chief Technology Officer
Head of Business Development

Phone: 973-967-9949

Email: lawrence@navikabio.com